Navigation Links
Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
Date:1/12/2011

iprofloxacin against B. anthracis, despite a less than optimal dose.  Solithromycin also delayed mortality in mice for days after dosing against F. tularensis.  Future studies will evaluate optimal doses of solithromycin based on PK/PD modeling and the current therapeutic regimen being tested in Phase 2.  

"Solithromycin is emerging as a very promising broad spectrum, well-tolerated antibiotic," said Prabhavathi Fernandes, Ph.D., Chief Executive Officer of Cempra Pharmaceuticals.  "Pre-clinical and clinical data collected to date show it to have a broad activity spectrum and to be well tolerated in healthy volunteers.  Its flexibility of administration including once-daily oral, oral suspension and intravenous, its high tissue penetration, especially in blood and lung including lung macrophages, and its ability to target intracellular pathogens, demonstrate its significant potential for both civilian and bio-defense applications.  Building a safety and efficacy database for civilian bacterial pneumonia coupled with meeting the animal rule, which is a unique regulatory mechanism to gain FDA approval based on animal data when well-controlled efficacy studies in humans is not ethical or feasible, could be a path forward for approval for bio-defense indications."

About solithromycin (CEM-101)Solithromycin is the first fluoroketolide with a number of attributes that may provide clinically important advantages over several comparator products:

  • 8 to 16 times more potent than azithromycin and is active against organisms that have become resistant to azithromycin
  • Potent in vitro activity against all important respiratory pathogens, including pneumococci, beta-hemolytic streptococci, staphylococci, Hemophilus, Legionella, Mycoplasma, Moraxella and Chlamydophila
  • Potent in vitro activity against other medically significant pathogens including CA-MRSA, M. avium, malaria, enteroc
    '/>"/>

  • SOURCE Cempra Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
    2. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
    3. Savient Pharmaceuticals Provides Business Update
    4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    5. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    6. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
    7. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    8. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
    9. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
    10. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    11. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of the ... Maroulis, Pharm.D. to the newly created position of Vice ... position, Dr. Maroulis will continue to manage the entire ... multi-site pharmacies as the company expands. Dr. Maroulis has ... he has served in many different capacities in the ...
    (Date:12/19/2014)... Dec. 19, 2014 Decision Resources Group finds ... at a 12 percent compound annual growth rate through ... aging population and the increasing adoption of dental implants. ... will also spur demand for dental biomaterials because ... and periodontal treatments. Other key findings from ...
    (Date:12/19/2014)... MA (PRWEB) December 18, 2014 LayerBio ... for ophthalmology and wound care. The National Eye Institute ... awarded LayerBio a Phase I SBIR grant to develop ... Cataracts are the most common cause of vision loss ... of blindness worldwide. According to Dr. Ken Mandell, LayerBio’s ...
    (Date:12/19/2014)... In contrast to traditional LED lights where ... Valoya uses proprietary LED technology to incorporate their spectra ... which is critical in low proximity installations. The Valoya ... its lifetime which is up to four times longer ... investment cost was clearly higher when compared to traditional ...
    Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
    ... BARCELONA, Spain , June 14 Data ... in Barcelona , highlights the impact of febrile ... patients. The IMPACT NHL study showed that unplanned hospitalisations, ... to suboptimal relative dose intensity (RDI) of chemotherapy were ...
    ... ... Mogil, an internationally-renowned leader in pain research, will be presenting “What’s Wrong with ... be held October 4-5, 2010 in Philadelphia, Pennsylvania. , ... Minneapolis, MN (PRWEB) June 10, ...
    ... ... oldest buildings on earth and a “fascinatingly weird” ancient culture. , ... (PRWEB) June 11, 2010 -- U.S. nonprofit The ... a simple introduction to megalithic architects in Frequently Asked Question format. With content drawn ...
    Cached Biology Technology:New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 2New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 3New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 4New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 5New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 6New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 7New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 8New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 9Jeffrey Mogil to Speak on Animal Models of Pain at Arrowhead's 4th Annual Pain Therapeutics Summit 2New tool for exploring the ancient world. 2
    (Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
    (Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
    (Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
    Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
    ... recently published their joint findings that fatal prion diseases, which ... Findings published this month in the peer-reviewed journal, ... to seven months before an animal shows physical signs of ... brain was being eradicated. This member of the prion family ...
    ... have demonstrated, for the first time, a graphene-based ... cells and capable of recording the electrical signals ... for further investigation of a promising new material. ... leading contender for future biomedical applications requiring a ...
    ... Take a Petri dish containing crude petroleum and it ... make up the fossil fuel. Sprinkle mushroom spores over the ... an incubator, and surprise, the petroleum and its smell will ... professor of biological sciences and researcher at the University of ...
    Cached Biology News:Medical researchers in Canada and the US discover hidden side of prion diseases 2Biocompatible graphene transistor array reads cellular signals 2Biocompatible graphene transistor array reads cellular signals 3Petroleum-eating mushrooms 2Petroleum-eating mushrooms 3Petroleum-eating mushrooms 4
    ... suit the widest possible range of sample ... Labware carriers can be placed at any ... for the user, thanks to a numbered ... guided into position. This allows easy removal ...
    ... Sac-Cel (Second Antibody Coated CELlulose) was developed ... of Dartford, Kent, one of the earliest ... IDS acquired the product range in 1987. ... clinical biochemists developing their own "in house" ...
    ... N,N- bis- (3-D-Gluconamidopropyl)deoxycholamide ... analog of CHAPS and CHAPSO. Has reduced ... anion exchange chromatography on DEAE-cellulose. Aggregation number: ... Soluble in H 2 O. Aggregation number ...
    ... N-Dodecyl-N,N-(dimethylammonio)butyrate White crystalline solid. ... to DDMAU (Cat. No. 252005) but differing ... More efficient for the extraction of mycoplasma ... Purity: ≥98% by TLC. Soluble ...
    Biology Products: